Leadership changes at Biogen Idec, Exelixis, Abbott, Pierre Fabre; Shionogi reorganizes in USA
US biotechnology firm Biogen Idec has announced that George Scangos has been appointed chief executive, effective July 15. Dr Scangos, who replaces Jim Mullen, who recently retired under pressure from billionaire investor Carl Icahn, will also be named to the board of directors.
Dr Scangos, aged 62, brings nearly 25 years of experience in the biotechnology and pharmaceutical industries. He joins Biogen Idec from Exelixis, where he has served as president and CEO since 1996. Previously, Dr Scangos spent 10 years at Bayer Corp. Before joining Bayer in 1987, Dr Scangos was a Professor of Biology at Johns Hopkins University for six years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze